Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141) Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., Canton, D. A., Twitty, C., Foerter, K., Joshi, R. AMER ASSOC CANCER RESEARCH. 2020
View details for DOI 10.1158/1538-7445.SABCS19-P3-09-04
View details for Web of Science ID 000527012501378